Contract development and manufacturing organisation (revision 16)
Old revision·10:56, 21 May 2025·CustomsClarke
| Contract development and manufacturing organisationSupply chain role | |
|---|---|
| Abbreviation | CDMO |
| Function | Development and manufacture to a customer specification |
| Consequence | Brand and manufacturer are frequently different |
| Topic infobox · conventions | |
A contract development and manufacturing organisation (CDMO) develops processes and manufactures material to the specification of a customer who sells it under their own name. The arrangement is ordinary across the pharmaceutical and fine-chemical industries and is not in itself remarkable.[1]
Its consequence for anyone reading supplier documentation is that the organisation named on a catalogue is not necessarily the organisation that made the material. A brand may be a manufacturer, a distributor of its own contract-manufactured material, or a reseller of another's — and the documentation may not distinguish these.[2]
The distinction matters for traceability rather than for quality as such. Contract-manufactured material with an intact record chain is fully traceable; the failure mode is a chain broken at the transfer, which is a records question. See Repackaging.[1]
What a CDMO does
[edit]Services span process development, analytical method development, scale-up, manufacture and, in some cases, fill-finish. A customer may buy any subset: a fully developed process transferred in, or a molecule and a target specification with everything else contracted out.[1]
For peptides the capability that matters is synthesis at scale with the associated preparative chromatography, since the purification step is the one that requires the largest capital equipment. A house able to synthesise but not to purify at scale is limited to crude supply, and the distinction shows up in the specification a customer can be offered rather than in any claim about capability.[3]
Quality responsibility is defined by a quality agreement between the parties. In regulated manufacture the marketing authorisation holder remains responsible for the product regardless of who made it, and the agreement allocates the practical obligations.[1]
Consequences for reading documentation
[edit]A certificate identifies the organisation that performed the determinations, which may or may not be the manufacturer and may or may not be the seller. Where the three differ and the document names only one, the others are simply not established by the document.[2]
| Named on the document | What it establishes |
|---|---|
| Testing organisation | Who performed the determinations |
| Manufacturing site | Where the material was made |
| Seller | Who is selling it |
Most research-chemical certificates name one of these. That is a limitation of the document rather than evidence about the arrangement behind it, and inferring a specific structure from a document's silence is unsound.
Where a claim about in-house manufacture is made, it is checkable in principle against corporate registration and facility records — the kind of documentary review described at VendorInvestigate — and not checkable at all by analysis of the material.[4]
See also
References
- ^ a b c d International Council for Harmonisation, Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients (2000).
- ^ a b ISO 9001:2015, Quality management systems — Requirements.
- ^ United States Pharmacopeia, General Chapter <1503>, Quality Attributes of Synthetic Peptide Drug Substances.
- ^ PeptidePedia Wiki community test-report tally, 2024–2026 (self-reported; see Project:Sourcing guidelines).